Table 2. Predicted median PFS and OS by baseline FKSI-15 score in patients on sunitinib.
| Baseline FKSI-15 score | Predicted PFS (95% CI) n=372 | Predicted OS (95% CI) n=372 |
|---|---|---|
| 0 | 12.94 (7.19, 23.30) | 10.10 (5.89, 17.34) |
| 5 | 14.86 (8.78, 25.16) | 13.16 (8.14, 21.28) |
| 10 | 17.06 (10.71, 27.18) | 17.14 (11.25, 26.11) |
| 15 | 19.59 (13.06, 29.38) | 22.32 (15.53, 32.07) |
| 20 | 22.49 (15.92, 31.78) | 29.06 (21.43, 39.42) |
| 25 | 25.81 (19.37, 34.41) | 37.85 (29.53, 48.53) |
| 30 | 29.64 (23.53, 37.34) | 49.30 (40.56, 59.91) |
| 35 | 34.03 (28.46, 40.69) | 64.20 (55.40, 74.40) |
| 40 | 39.07 (34.12, 44.75) | 83.62 (74.64, 93.67) |
| 45 | 44.86 (40.08, 50.20) | 108.90 (97.83, 121.21) |
| 50 | 51.50 (45.60, 58.16) | 141.82 (124.25, 161.88) |
| 55 | 59.13 (50.53, 69.20) | 184.70 (154.91, 220.23) |
| 60 | 67.89 (55.24, 83.43) | 240.55 (191.57, 302.05) |
Abbreviations: CI=confidence interval; FKSI-15=Functional Assessment of Cancer Therapy–Kidney Symptom Index–15 item; OS=overall survival; PFS=progression-free survival.
There were no observed scores below 20 points on the FKSI-15. As such, prediction estimates were extrapolations in this range and may not be as reliable as other prediction estimates where data were observed.